BCC Research Publishes A New Report On Global Markets For Reproductive Technologies

The global market for reproductive technologies and products is expected to reach nearly $16.1 billion in 2013. BCC Research projects the market to grow to nearly $19.6 billion by 2018, and register a five-year compound annual growth rate of 4.1% from 2013 to 2018.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This

SAMPLE FIGURE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTION AT ESTIMATED MANUFACTURERS’ SALES LEVELS, 2011-2018 ($ BILLIONS)

Wellesley, Mass (PRWEB) December 04, 2013

According to a new technical market research report, Human Reproductive Technologies: Products and Global Markets, from BCC Research (http://www.bccresearch.com), the global market for reproductive technologies and products is expected to reach nearly $16.1 billion in 2013. BCC Research projects the market to grow to nearly $19.6 billion by 2018, and register a five-year compound annual growth rate of 4.1% from 2013 to 2018.

Many factors influence the human reproductive arena. Countries differ in their approaches and acceptance of fertility, contraception and sexual dysfunction. Culture, religion and social environment all play a role. Depending on the country and position of women in the society, it can make a significant difference on how reproduction is treated. For example, the choice of contraception varies by country. In Japan, condoms and abortions are preferred to other methods. In India, sterilization is the preferred method of birth control, while in Africa, injectable birth control dominates. In China, the use of the coil is preferred. This difference in preference by country is also seen in both the fertility and sexual dysfunction areas as well.

In each of the three major areas of infertility, contraception and sexual dysfunction, there has been increasing interest and advancements. New developments in the area of contraception have stepped up the quest for easier, safer, and more convenient methods of contraception. A growing global population, improving access to healthcare, recognition of sexual dysfunction as a medical disorder, and growing demand for contraceptive and fertility products will drive steady growth in this market over the near term.

This report from BCC Research provides a comprehensive, up-to-date look at the market for reproductive technologies and products. It is designed to increase the awareness of the global reproductive market by identifying pharmaceutical preparations, devices, technologies, and important advancements within the industry. The study analyzes the new therapeutics and technologies for reproductive health and addresses issues and trends affecting the market. Manufacturers of pharmaceutical products, devices and technologies have stepped up discovery, as the engine driving growth in all markets is research and development.

The geographic scope of the report is global. The report reviews male and female reproductive health, presents standard pharmaceutical treatments and devices, and reviews technologies associated with reproductive health. The report also explores market size, identifies market participants and investigates pipeline products and technologies. The global market for reproductive technologies and products is divided into categories by treatment type and indication as follows, including infertility market—male and female factors, pharmaceuticals and future advancements (IVF, assistive reproductive technologies, and fertility diagnostics), contraception—pharmaceuticals and devices, and sexual dysfunction—pharmaceuticals and devices.

Each area is covered in detail, describing the disorder or treatment involved, identifying current products and treatments in the market in the base year 2013, measuring current market size and identifying current and potential market drivers, forecasting for 2018, assessing current and potential competitors and identifying current competitor market shares for the base year of 2013. The report is intended for decision-makers in the various areas of reproductive drugs and technologies, and it provides insight into those arenas for current and future development.


Contact

Attachments